This study is a single-arm, single-center exploratory clinical study. Twenty patients with early-stage HER2-positive breast cancer are planned to be included, and the primary objective is to evaluate the efficacy of neoadjuvant regimen of Pyrotinib in combination with trastuzumab + pertuzumab.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-06-10; most recent amendment 2022-01-04.